Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

2.4K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms.

Blood advances·2022
Same author

Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2021
Same author

An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.

Cell·2020
Same author

An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.

Cell·2019
Same author

Therapeutic targeting of cathepsin C: from pathophysiology to treatment.

Pharmacology & therapeutics·2018
Same author

A shocking diagnosis.

Journal of hospital medicine·2017

Related Experiment Video

Updated: Jul 15, 2025

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

12.3K

Update on Mast Cell Proteases as Drug Targets.

George H Caughey1

  • 1University of California at San Francisco.

Immunology and Allergy Clinics of North America
|September 27, 2023
PubMed
Summary

Mast cell proteases, including β-tryptases, chymases, and dipeptidyl peptidase-I, are therapeutic targets. Inhibitors show promise for asthma, ulcerative colitis, and bronchiectasis, with varying clinical trial outcomes.

Keywords:
Carboxypeptidase A3Cathepsin CCathepsin GChymaseDipeptidyl peptidase-ITryptase

More Related Videos

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.4K
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

10.4K

Related Experiment Videos

Last Updated: Jul 15, 2025

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

12.3K
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.4K
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

10.4K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Mast cells release proteases from granules upon degranulation.
  • These proteases are implicated in various diseases, including asthma, ulcerative colitis, and bronchiectasis.
  • Specific proteases like β-tryptases, chymases, and dipeptidyl peptidase-I are key targets for therapeutic intervention.

Purpose of the Study:

  • To evaluate the therapeutic potential of mast cell protease inhibitors.
  • To assess the clinical efficacy and safety of inhibitors targeting β-tryptases, chymases, and dipeptidyl peptidase-I.

Main Methods:

  • Preclinical studies of small-molecule and antibody-based inhibitors.
  • Early-phase and Phase II human clinical trials for different protease inhibitors.
  • Assessment of therapeutic benefits and safety profiles in human subjects.

Main Results:

  • β-tryptase inhibitors demonstrated preclinical promise and showed some benefit in early human trials.
  • Chymase inhibitors were safely administered in Phase II trials but did not show significant benefits.
  • Dipeptidyl peptidase-I inhibitors improved bronchiectasis, likely by inactivating the enzyme in neutrophils.

Conclusions:

  • Mast cell protease inhibitors represent a promising therapeutic strategy for various inflammatory and fibrotic diseases.
  • Clinical outcomes vary among different protease inhibitors, highlighting the need for target-specific approaches.
  • Further research is warranted to optimize the development and application of these inhibitors for specific conditions.